Chatham Lodging Trust's preferred stock offers an attractive 8.2% yield supported by a strong balance sheet and solid dividend coverage. The company reported a nearly 20% year-over-year increase in adjusted funds from operations (FFO) for Q2, with a 25% rise in per-share adjusted FFO, reinforcing confidence in sustained preferred dividend payments. Its net debt is conservatively managed at just over $400 million, representing 35% of book value and less than 25% of acquisition cost. While the common stock has risen 50%, the preferred shares remain a recommended buy for their risk-adjusted returns.
BDR Pharmaceuticals has filed a lawsuit against the FDA, disputing the agency's refusal to accept an abbreviated new drug application referencing Phathom Pharmaceuticals' VOQUEZNA. BDR claims the FDA wrongly extended Phathom's exclusivity period unde...
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
Veracyte's Decipher Prostate Genomic Classifier can predict which men with very high-risk nonmetastatic prostate cancer will benefit from adding abiraterone to androgen deprivation therapy (ADT). This finding, from a Phase III STAMPEDE trial analysis...
